Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000673090 | SCV000798258 | uncertain significance | GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis | 2018-03-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003764505 | SCV004604252 | pathogenic | Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis | 2023-10-13 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 591 of the GLB1 protein (p.Tyr591Cys). This variant is present in population databases (rs72555371, gnomAD 0.003%). This missense change has been observed in individual(s) with GM1-gangliosidosis (PMID: 10737981). ClinVar contains an entry for this variant (Variation ID: 948). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLB1 protein function. This variant disrupts the p.Tyr591 amino acid residue in GLB1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10737981). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000000998 | SCV000021148 | pathogenic | GM1-gangliosidosis, type I, with cardiac involvement | 2000-01-01 | no assertion criteria provided | literature only |